Despite the United States having had a biosimilar pathway for a decade now, the industry has launched just 17 biosimilars, well behind the pace in Europe and India. Several pieces of legislation have been introduced in Congress to help boost uptake, generate savings for payers and patients, and increase biosimilar access. However, not every bill is likely to become a law, as politics and money can often get in the way.
In an interview with the Center for Biosimilars, Venable’s Ha Kung Wong and April Breyer Menon discuss potential bills to improve biosimilar uptake and their chances for passage.
Listen to the podcast here.
